JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 106 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $27,000 | +22.7% | 3,578 | +11.6% | 0.00% | 0.0% |
| Q2 2021 | $22,000 | -40.5% | 3,207 | -10.2% | 0.00% | -50.0% |
| Q1 2021 | $37,000 | +27.6% | 3,573 | +3.5% | 0.00% | 0.0% |
| Q3 2020 | $29,000 | +3.6% | 3,451 | -14.4% | 0.00% | 0.0% |
| Q2 2020 | $28,000 | +460.0% | 4,033 | +321.9% | 0.00% | – |
| Q1 2020 | $5,000 | -95.3% | 956 | -92.1% | 0.00% | -100.0% |
| Q4 2019 | $106,000 | +55.9% | 12,150 | -39.7% | 0.01% | +20.0% |
| Q3 2019 | $68,000 | +172.0% | 20,139 | +300.1% | 0.01% | +150.0% |
| Q2 2019 | $25,000 | +177.8% | 5,034 | +249.6% | 0.00% | +100.0% |
| Q1 2019 | $9,000 | 0.0% | 1,440 | -48.9% | 0.00% | 0.0% |
| Q4 2018 | $9,000 | -30.8% | 2,820 | +38.6% | 0.00% | 0.0% |
| Q3 2018 | $13,000 | -99.2% | 2,034 | +911.9% | 0.00% | – |
| Q2 2018 | $1,540,000 | +25566.7% | 201 | -23.6% | 0.00% | -100.0% |
| Q1 2018 | $6,000 | -25.0% | 263 | -46.3% | 0.00% | 0.0% |
| Q3 2017 | $8,000 | – | 490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $20,045,000 | 88.84% |
| TRV GP III, LLC | 3,048,780 | $22,652,000 | 4.30% |
| Logos Global Management LP | 2,000,000 | $14,860,000 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,559 | $1,550,000 | 0.88% |
| PFM Health Sciences, LP | 3,848,822 | $28,597,000 | 0.84% |
| Yorktown Management & Research Co Inc | 113,200 | $841,000 | 0.63% |
| Moloney Securities Asset Management, LLC | 282,250 | $2,097,000 | 0.38% |
| PATHWAY CAPITAL MANAGEMENT, LP | 84,763 | $630,000 | 0.30% |
| Sofinnova Investments, Inc. | 637,347 | $4,735,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $2,047,000 | 0.23% |